行情

IOVA

IOVA

Iovance
NASDAQ

实时行情|Nasdaq Last Sale

27.94
-2.00
-6.66%
盘后: 27.94 0 0.00% 16:59 04/01 EDT
开盘
28.71
昨收
29.94
最高
31.09
最低
27.77
成交量
189.05万
成交额
--
52周最高
38.92
52周最低
9.52
市值
35.34亿
市盈率(TTM)
-17.6122
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测IOVA价格均价为40.00,最高价位60.00,最低价为35.00。

EPS

IOVA 新闻

更多
  • 波音将向员工提供工龄买断和提前退休计划
  • 新浪财经 · 1小时前
  • 新华社:新冠肺炎疫情或致美国制造业深陷衰退危机
  • 新华网 · 2小时前
  • 沪指低开高走 疫情数据双重打击、隔夜美股重挫4.4%
  • 新浪财经 · 2小时前
  • 菲律宾总统下令隔离期间制造麻烦者格杀勿论
  • 新浪财经 · 2小时前

所属板块

生物技术和医学研究
-4.52%
制药与医学研究
-2.91%

热门股票

代码
价格
涨跌幅

IOVA 简况

Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.
展开

微牛提供Iovance Biotherapeutics Inc(NASDAQ-IOVA)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的IOVA股票新闻,以帮助您做出投资决策。